CD38 and liver cancer: Loading CD38 siRNA into EVs derived from bone marrow mesenchymal stem cells, which are then taken up by liver cancer cells, downregulates CD38 enzyme activity and adenosine secretion, thereby promoting the differentiation of macrophages toward the M1 phenotype and reducing the release of PD-L1-EVs189.